

JNJ26854165/Serdemetan


Cat. # SI9815

Background: An oral, phase 1 hdm2 antagonist. Binds the ring domain of MDM2 and inhibits survival in cancer cells¹.

Application: Cell-based and *in vitro* studies of hdm2 function

Product Information:

CAS No.	881202-45-5
Purity:	>99%
Molecular Weight:	328.41 Da
Physical State:	Powder
Quantity:	5mg
Solubility:	DMSO (66mg/ml); Ethanol (<2mg/ml); Water (<1mg/ml)
Storage:	Store desiccated as supplied at -20°C for 2 years.



Formula:

C₂₁H₂₀N₄

References

- 1) Kojima, K., J. K. Burks, et al. (2010). "The novel tryptamine derivative JNJ-26854165 induces wild-type p53- and E2F1-mediated apoptosis in acute myeloid and lymphoid leukemias." *Mol Cancer Ther* 9(9): 2545-2557.

All products are for research use only • Not intended for human or animal diagnostic or therapeutic uses

Copyright © 2013 LifeSensors, Inc. All Rights Reserved